Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Cidara Therapeutics Announces Offering of Common Stock and Warrants

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with...

CDTX : 5.43 (+4.42%)
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and...

CDTX : 5.43 (+4.42%)
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs...

MLNT : 5.30 (-14.86%)
TBPH : 23.14 (+0.52%)
CFRX : 1.87 (+1.08%)
TTOO : 8.69 (-0.80%)
MTFB : 8.30 (-0.72%)
ASNS : 15.75 (-5.18%)
SCYX : 1.73 (+8.81%)
CDTX : 5.43 (+4.42%)
NBRV : 4.52 (-1.53%)
PRTK : 10.40 (-0.95%)
SPRO : 10.58 (-5.54%)
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead...

CDTX : 5.43 (+4.42%)
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms

CDTX : 5.43 (+4.42%)
Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin

Stock Monitor: BioTime Post Earnings Reporting

CDTX : 5.43 (+4.42%)
Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock

Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.

CDTX : 5.43 (+4.42%)
Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections

CDTX : 5.43 (+4.42%)
Shares of Progenics Pharm Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (PGNX , TTOO, CDTX, TGTX , ADRO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

PGNX : 7.51 (-1.44%)
TTOO : 8.69 (-0.80%)
CDTX : 5.43 (+4.42%)
Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation...

CDTX : 5.43 (+4.42%)
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December...

CDTX : 5.43 (+4.42%)
The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair

The Antimicrobials Working Group (AWG) announced today that Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics, has been appointed as Vice Chair, joining Vice Chair Evan Loh, M.D., President,...

CDTX : 5.43 (+4.42%)
PRTK : 10.40 (-0.95%)
Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its lead antifungal...

CDTX : 5.43 (+4.42%)
Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of papers published as a Journal of Antimicrobial...

CDTX : 5.43 (+4.42%)
Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the STRIVE trial, a...

CDTX : 5.43 (+4.42%)
Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2017...

CDTX : 5.43 (+4.42%)
Cidara Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Cidara Therapeutics, Inc. (NASDAQ: CDTX) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:05 PM Eastern...

CDTX : 5.43 (+4.42%)
5 Biotech Stocks Well Poised to Surpass Expectations in Q3

The pharma and biotech industry has demonstrated strength

PBYI : 51.60 (+1.28%)
RGEN : 43.03 (+0.54%)
CDTX : 5.43 (+4.42%)
INO : 4.84 (-0.41%)
SBBP : 7.30 (-2.67%)
What's in the Cards for Merrimack (MACK) in Q3 Earnings?

Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

AGEN : 3.47 (-0.29%)
RGNX : 47.20 (+0.96%)
CDTX : 5.43 (+4.42%)
MACK : 8.49 (-1.62%)
What's in the Cards for Repros (RPRX) This Earnings Season?

Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

AGEN : 3.47 (-0.29%)
RPRX : 0.67 (-1.03%)
RGNX : 47.20 (+0.96%)
CDTX : 5.43 (+4.42%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar